Roivant Sciences company profile
Company profile
Roivant Sciences has 721 employees and is headquartered in London, United Kingdom.
Headquartered in London and founded in 2014, Roivant Sciences Ltd. develops medicines and related technologies aimed at immune-mediated and cardiopulmonary conditions. Its clinical pipeline is built around antibodies such as IMVT-1402 and batoclimab, the small molecule brepocitinib, and mosliciguat, an inhaled sGC activator that is the lead program and targets pulmonary hypertension linked to interstitial lung disease. These candidates are still in development, with target indications that include Graves' disease, rheumatoid arthritis, myasthenia gravis, thyroid eye disease and dermatomyositis. The company also offers lipid nanoparticle and ligand conjugate delivery platforms.
In the fiscal year ended March 2026, Roivant reported revenue of 8.3 million US dollars, a decline of 71.6% from the previous year, and a net loss of 299.8 million US dollars. The company had 721 employees.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Headquarters
- 50 Broadway, SW1H 0DB, London
- Employees
- 721
- Chief executive
- Matthew Gline
- Founded
- 2014
- Fiscal year
- April - March
- Listing
- ROIV · NASDAQ
- Currency
- USD
- ISIN
- BMG762791017
- Website
- roivant.com
Roivant Sciences and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Roivant SciencesROIV | United States | $28.64B | 721 | -3,226.3% | — |
| InsmedINSM | United States | $26.58B | 1,664 | -41.7% | — |
| IncyteINCY | United States | $24.66B | 2,844 | 32.2% | 61.7 |
| Revolution MedicinesRVMD | United States | $37.27B | 883 | -853.0% | — |
| Alnylam PharmaceuticalsALNY | United States | $22.11B | 2,500 | 19.5% | 8.34 |
| BioNTechBNTX | United States | $21.22B | 7,807 | -55.4% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
